Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer

COMMENTED

Genitourinary CancerNuclear Medicine

¹⁷⁷Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

★ 3 Recommended and commented by Prof. Dr Ken Herrmann, Faculty Member

Lancet

Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K, PSMAfore Investigators

doi: 10.1016/S0140-6736(24)01653-2

Genitourinary Cancer

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients

Prostate

Tanegashima T, Shiota M, Tsukahara S, Mutaguch J, Goto S, Kobayashi S, Matsumoto T, Eto M

doi: 10.1002/pros.24769

Genitourinary Cancer

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Eur Urol

Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ

doi: 10.1016/j.eururo.2024.08.021

COMMENTED

Genitourinary CancerNuclear Medicine

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)

★ 2 Recommended and commented by Prof. Dr Ken Herrmann, Faculty Member

Radiology

Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K

doi: 10.1148/radiol.233460

CHICAGO 2025

Genitourinary Cancer

PSMA-delay castration: ¹⁷⁷Lu-PSMA-617 versus observation in patients with PSMA-positive oligometastatic prostate cancer

Genitourinary Cancer

Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

Prostate

Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H

doi: 10.1002/pros.24880

Genitourinary Cancer

A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer

Eur Urol

Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA

doi: 10.1016/j.eururo.2024.09.020

Genitourinary Cancer

Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

JAMA Netw Open

George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, Hlebec V, Shore ND

doi: 10.1001/jamanetworkopen.2024.29783

Genitourinary Cancer

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update

J Clin Oncol

Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE Jr, Parikh RA

doi: 10.1200/JCO-25-00007

Related content

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)

PSMA-delay castration: 177Lu-PSMA-617 versus observation in patients with PSMA-positive oligometastatic prostate cancer

Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer

Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update

¹⁷⁷Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)

PSMA-delay castration: ¹⁷⁷Lu-PSMA-617 versus observation in patients with PSMA-positive oligometastatic prostate cancer